Cardiac Biomarkers Market Size, Share, Growth Report 2035

Cardiac Biomarkers Market Overview:

Global Cardiac Biomarkers Market is expected to garner $2,085.9 million by 2020, registering a CAGR of 18.9% during the forecast period 2015-2020. The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state and used for diagnostic and prognostic purposes associated with heart. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others. Cardiac biomarkers market has witnessed a greater demand over the past five to six years.

Ability of cardiac markers for accurate and rapid prediction of heart failure after the onset of chest pain has added boost to the market growth. In addition, promising features such as high accuracy, quick outcomes and economic pricing of cardiac point of care (POC) testing is driving the growth of cardiac biomarker market, globally. To keep the momentum of cardiac marker tests, the key manufacturers offers customized solutions. The commercial application of multi-menu options for cardiac testing using different combinations of cardiac biomarkers and target-oriented solutions are the key opportunities of the market. However, limited specificity in some cases and side effects such as skeletal muscle injury is restraining the growth cardiac biomarkers markets.

The Global cardiac biomarkers market is segmented based on type, application, location of testing and geography. Based on cardiac biomarker type, the market is segmented into Creatine Kinase (CK-MB), Troponins T and I, myoglobin, BNPs, IMA and others. Troponins I and T are the highest revenue-generating segment in the overall cardiac biomarker market due to its prodigious specificity and its ability to accurately detect the cardiac events of Acute Coronary Syndrome (ACS).

Based on application, the market is segmented into myocardial infarction, congestive heart failure, Acute Coronary Syndrome, atherosclerosis and others. Myocardial infarction (MI) holds the highest market share in the global cardiac biomarker market followed by Acute Coronary Syndrome (ACS) due to the highest prevalence rate among cardiovascular diseases (CVDs). The location of testing segment is classified as point of care testing and laboratory testing. Doctors and clinicians largely prefer point of care cardiac testing for quick monitoring patients with chest pain in an emergency care unit, therefore, accounting the fastest CAGR. However, laboratory testing is generating larger revenue in comparison to point of care testing.

Based on geography, the global cardiac biomarker market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America leads the global market, owing to the high demand for cardiac testing, high CVD prevalence rate and growing awareness towards cardiac diagnostics solutions. Asia-Pacific is growing at the fastest CAGR due to the modernization, increasing disposable incomes and rising affordability for the advanced cardiac treatments.

Key companies profiled in this market include Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Alere Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, BioMerieux, Randox laboratories, Beckman Coulter and Thermo Fisher Scientific. Product launch and technological advancements are the few strategies adopted by the key players of global market. The companies are currently focusing on innovative technologies such as automated, multi-assay using combinations of cardiac biomarkers and point-of-care cardiac biomarker devices.

CARDIAC BIOMARKERS MARKET KEY BENEFITS:

Extensive coverage of the global market including drivers, restraints and opportunities would help professionals to better understand the market behavior.
Country level analysis has been done to provide micro market size of cardiac biomarker in different regions
The market estimations are made in the report by conducting high-end analysis of the key market segments for the forecast period 2014-2020
A comprehensive analysis of the market scenario in terms of types, applications, location of testing and geography helps identify the growth opportunities in the global market.
The market attractiveness analysis for the Global Myocardial markers provides strategic assistance to the decision makers
Key market players within the global market are profiled during the study and their strategies are analysed thoroughly, which helps in understanding competitive outlook of this market

Cardiac Biomarkers Market Report Highlights

Aspects	Details
By Type	Myocardial muscle Creatine Kinase (CK-MB) Troponins (T and I) Myoglobin Brain Natriuretic Peptide (BNPs) or NT-proBNP Ischemia Modified Albumin (IMA) Others
By APPLICATION	Myocardial Infarction Congestive Heart Failure Acute Coronary Syndrome Atherosclerosis Others
By LOCATION OF TESTING	Point of care testing Laboratory testing
By GEOGRAPHY	North America Europe Asia-Pacific LAMEA
Key Market Players	Siemens Healthcare, Becton, Dickinson And Co., Abbott laboratories, BioMerieux, Bio-Rad Laboratories, Alere Inc., Randox laboratories, Beckman Coulter, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc.